Compare Taskus Inc (TASK) vs GeneDx Holdings Corp (WGS) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Taskus Inc vs GeneDx Holdings Corp — how do they compare? Taskus Inc trades at $5.86 (market cap $532.07M), while GeneDx Holdings Corp trades at $61.92 (market cap $1.80B). The key difference: GeneDx Holdings Corp is far larger — about 3.4× Taskus Inc's market cap, and GeneDx Holdings Corp is trading nearer its 52-week high, Taskus Inc nearer its low. Which is the better fit depends on your goals.
| TASK | WGS | |
|---|---|---|
Market Cap | $532.07M | $1.80B |
Sector | Technology | Technology |
52-Week High | $18.21 | $167.51 |
52-Week Low | $4.57 | $34.51 |
Enterprise Value | $927.77M | $1.80B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
TaskUs (TASK) trades at $5.81, down 0.34% on the day, with a bullish technical signal from moving averages but bearish oscillators. The company reported Q1 2026 earnings of $0.35 per share, missing estimates, after beating in the prior two quarters. Revenue reached $1.18 billion in 2025 with net income of $102.28 million, showing strong profitability. Analysts maintain a consensus buy rating with a $9.50 price target, suggesting significant upside potential.
The stock appears undervalued with a P/E of 5.16 and P/S of 0.45, supported by robust ROE of 26.52%. Risks include recent earnings miss and competitive pressures in digital services. Positive cash flow and debt reduction trends provide fundamental strength, but investor sentiment is mixed amid technical overbought signals.
GeneDx Holdings (WGS) trades at $60.65, down 4.46% amid a bearish technical signal and negative profitability. Recent earnings showed a Q1 2026 miss after two prior beats, with revenue growth but widening losses projected for 2026. The stock faces significant headwinds from multiple securities class action lawsuits alleging misrepresentations, with a deadline of August 3, 2026.
Despite a high analyst buy consensus (90.9%) and a $75.40 price target implying 24% upside, risks are elevated due to litigation, negative margins, and a high EV/EBITDA of 161.17. The upcoming Q2 2026 results on August 3 will be critical for investor confidence, but the legal overhang and fundamental challenges suggest cautious near-term outlook.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Taskus Inc
TaskUs Inc is a provider of outsourced digital services and next-generation customer experience to innovative and disruptive technology companies. It serves clients in the fastest-growing sectors, including social media, e-commerce, gaming, streaming media, food delivery and ridesharing, HiTech, FinTech and HealthTech.
Read more on TASK →About GeneDx Holdings Corp
GeneDx is a patient-centered health intelligence company that specializes in transforming healthcare through the application of genomics. It combines advanced technology with one of the world's largest rare disease genomic datasets to provide clinical-grade exome and genome sequencing, enabling precise and rapid diagnosis for patients with complex medical conditions.
Read more on WGS →
